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Background
The HIV-neutralizing activity of monoclonal antibodies
2F5, 4E10, and Z13 have shown that the membrane-proxi-
mal external region (MPER) of HIV Env is an important
vaccine target, but development of an immunogen that eli-
cits similar virus-neutralizing antibody responses against
the MPER from a wide range of subtypes has been difficult
to achieve. It has been proposed that a MPER immunogen
must be membrane-associated to adopt the conformation
needed to elicit broadly neutralizing antibodies, and
accordingly, we have developed Vesicular Stomatitis Virus
(VSV) Vectors that express membrane-anchored MPER
epitopes.
Methods
Replication-competent and single-cycle VSV vectors have
been developed that express a truncated VSV G protein
(G-Stem) in which the natural G ectodomain is replaced
with MPER sequence (GStemMPER). The nucleotide
sequence of GStemMPER has been optimized by compu-
ter based algorithms to ensure genetic stability. Several
VSV vector modifications are also introduced for directing
immune responses towards MPER rather than G. Those
strategies include relocation of GStemMPER and VSV G
glycoprotein to achieve maximal MPER expression while
minimize the anti-vector immunity, incorporation of dif-
ferent VSV G serotypes and pseudotyping single- cycle
VSV vectors with various types of glycoproteins.
Results
Western blot analysis confirmed expression of MPER epi-
topes. Assessment by FACS showed the cell surface MPER
being recognized by 2F5 and 4E10 monoclonal antibodies.
Immunoprecipitation study further proved incorporation
of MPER into viral particles.
Conclusion
Multiple VSV-GStemMPER vectors are being evaluated in
small animal studies to compare their immunogenicity
and whether the membrane-anchored form of the MPER
immunogen elicits humoral responses with a broad range
of HIV neutralizing activity.
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